Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combined Exercise and Protein Supplementation to Preserve Skeletal Muscle During GLP-1 Receptor Agonist Treatment in People With Type 2 Diabetes: A Randomized Controlled Multicenter Trial

NCT07926152 is registered in ClinicalTrials.gov with German Diabetes Center as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07926152 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Combined Exercise and Protein Supplementation to Preserve Skeletal Muscle During GLP-1 Receptor Agonist Treatment in People With Type 2 Diabetes: A Randomized Controlled Multicenter Trial
Lead sponsor
German Diabetes Center
Phase
Not applicable
Overall status
Not yet recruiting
Start date
February 1, 2027
Completion date
January 31, 2030
Enrollment
94 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

obesity & overweight, sarcopenia, type 2 diabetes (t2dm)

Arms

As registered; 2 arms.

  • Exercise and Protein Supplementation ExperimentalStandardized lifestyle counseling, Supervised exercise training, protein supplement

    Participants continue their GLP-1 receptor agonist therapy (semaglutide or tirzepatide) as prescribed by their treating physician and receive one standardized lifestyle counselling session on nutrition and physical activity at baseline. In addition, they take part in a 24-week supervised training program with three sessions per week at the study center, alternating between full-body resistance training, high-intensity interval training on a cycle ergometer, and a combined session. Training intensity is progressively increased and individually adjusted. Participants also take 25 g of whey protein isolate daily, directly after each training session or in the morning on training-free days.

  • Usual Care Active comparatorStandardized lifestyle counseling

    Participants continue their GLP-1 receptor agonist therapy (semaglutide or tirzepatide) as prescribed by their treating physician and receive one standardized lifestyle counselling session on nutrition and physical activity at baseline. They do not take part in the supervised training program and do not receive protein supplementation.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Change in Contractile Thigh Muscle Volume Baseline to week 24

    Change in contractile thigh skeletal muscle volume (mL), assessed by magnetic resonance imaging (MRI). Contractile thigh muscle volume is defined as the sum of the bilateral anterior (quadriceps femoris, sartorius, tensor fasciae latae) and posterior (gluteal muscles, iliopsoas, adductors, hamstrings) thigh skeletal muscle volume minus intramuscular adipose tissue (IMAT) volume.

Lead sponsor's other trials

German Diabetes Center, most recent start first.

Similar trials

Same condition (Sarcopenia) and phase, most recent start first.